Presentation (CTI)

OBJECTIVES: To evaluate the three-year budget impact of incorporating finerenone as an adjunct to standard therapy for HFpEF and HFmrEF from a general U.S. payer perspective, using real-world cost inputs and clinical effectiveness data from the FINEARTS-HF trial.
METHODS: A static Excel-based cohort model was developed comparing the current standard of care with standard of care plus finerenone. The analysis included direct medical costs, including drug acquisition and hospitalization costs, derived from the 2023 Medical Expenditure Panel Survey database, and hospitalization reduction rates from the FINEARTS-HF trial. Uptake assumptions of 2 percent, 6 percent, and 10 percent over three years were modeled, with annual and cumulative cost outcomes evaluated. A one-way sensitivity analysis assessed the impact of uncertainty in key model inputs.
RESULTS: Over three years, cumulative drug costs for finerenone were estimated at 3.21 billion dollars, while avoided hospitalization savings totaled 176 million dollars, resulting in a net budget impact of 3.03 billion dollars. Approximately 5.5 percent of drug costs were offset by hospitalization savings. Model results were most sensitive to assumptions regarding hospitalization costs and finerenone acquisition costs.
CONCLUSIONS: Adding finerenone to standard of care for HFpEF and HFmrEF substantially increases short-term healthcare costs, with limited cost offset from reduced hospitalizations. These findings provide timely insights for U.S. payers in anticipation of regulatory approval and market entry.